Price
No data yet.
Social Signal Score
Analyst Ratings
5 analystsRevenue
$773.0K+24.48%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- E. Rand Sutherland
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 75
- Beta
- 1.39
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 13.71
Financials
Revenue
$773.0K+24.5%Net Income
$-39.70MEBITDA
$-39.70MFree Cash Flow
$-35.62MEPS (diluted)
$-0.73Shares Outstanding (diluted)
54.57M+50.2%Operating Expenses
$43.14MCash & Debt
$261.31MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.85M | $-143.44M | $-2.66 |
| 2024 | $2.37M | $-62.81M | $-1.49 |
| 2023 | $2.38M | $-20.54M | $-1.05 |
| 2022 | $1.21M | $-23.87M | $-0.66 |
Valuation
UPBhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+25.00%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·28d ago·Neutral
…s by evaluating a 400 mg quarterly regimen of verekitug in broad patient populations – WALTHAM, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for severe inflammatory respiratory diseases, today presented results from the Phase 2 VALIANT clinical trial evaluating the safety and efficacy of verekitug in adults with severe asthma in a late-breaking oral presentation at the European Respiratory Society (ERS) Congress 2026 i…
View source ↗ - Newsglobenewswire.com·35d ago·Neutral
…ulations – – The Company remains on track to initiate both Phase 3 trials in Q1 2027 – WALTHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for severe inflammatory respiratory diseases, today announced its pivotal Phase 3 development plans for verekitug in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP).
View source ↗ - Newszacks.com·55d ago·Negative
Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates Upstream Bio, Inc. (UPB) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to a loss of $0.74 per share a year ago.
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $-0.73 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$-0.73 vs $-0.78beat
- Wed, May 13$-0.75 vs $-0.75beat
- Thu, Mar 26$-0.79 vs $-0.73miss
- Wed, Nov 5$-0.63 vs $-0.78beat
- Wed, Aug 6$-0.74 vs $-0.61miss
- Tue, May 6$-0.51 vs $-0.49miss
Estimates and results for UPB via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by UPB officers and directors.
- Bought
- $48.0m
- Sold
- $105k
5 trades
15 trades
- Gray Michaelsold
- Ambrose Allisonsold
- Deykin Aaronsold
- Sutherland Everett Randsold
- Houghton Adamsold
- Gray Michaelsold
- Sutherland Everett Randsold
- Houghton Adamsold
80 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in UPB.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.